Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CSPI on AER bill

This article was originally published in The Tan Sheet

Executive Summary

The Center for Science in the Public Interest applauds the passage of the Dietary Supplement & Nonprescription Drug Consumer Protection Act Dec. 11 and says it hopes Congress "now provides sufficient funding so that the FDA can quickly respond to reports of adverse reactions and promptly remove hazardous products from the marketplace". Both consumer groups and major industry trade groups campaigned for the bill. "It's refreshing, and it's a pleasure, to see that those who are historically critical of the industry have been, I think, pleasantly surprised that the industry worked very hard to try and help move the bill," United Natural Products Alliance Executive Director Loren Israelsen said. "I hope that this kind of re-restores a bridge and a dialogue so that we can move on now to other issues," he added...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS100044

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel